Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR15: Combination Immunotherapy for Metastatic Colorectal Cancer
NCT06149481Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules, Vaccines & Immunotherapeutics, Viral Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of SX-682 in colorectal cancer (CRC), sponsored by National Cancer Institute. Started Mar 2024; status: recruiting.
02
Drugs
SX-682
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06149481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06149481.